Hosted on MSN

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with ...
ascopubs.org

The performance of MTAP homozygous deletion detection based on next-generation sequencing technology.

Dual-omic analysis to reveal gene regulatory network of immune landscape in childhood solid tumors and implications for immunotherapy. Phase 1/2 study of TSN222, a novel dual action tumor immune ...
Hosted on MSN

MTAP-deficient cancer cells share signals that silence immunity

MTAP encodes methylthioadenosine phosphorylase, an enzyme in the methionine salvage pathway that recycles methylthioadenosine to methionine. The gene resides on chromosome 9p21.3, adjacent to the ...
La Grande Observer

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...
Nasdaq

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...